Diabetic Gastroparesis Study 05

Summary

This open-label study is to assess the safety of continued treatment with relamorelin for participants who previously completed the RLM-MD-03 \[NCT03420781\] or RLM-MD-04 \[NCT03383146\] study and to provide treatment for these participants until relamorelin becomes commercially available or the Sponsor terminates development.

Timeline

Start

2018-12-20

Primary completion

2020-10-05

Completion

2020-10-05

Outcome

Outcome not reported

Stopped (Business): “The Relamorelin program is being terminated solely based on a business decision.”

Drugs

Indications